Grufity logo
Grufity logo
AXNX

AXNX - Axonics Modulation Technologies Inc Stock Price, Fair Value and News

$0.75-0.26 (-25.74%)
Market Closed as of 26 Oct 2026, 04:00 pm ET

AXNX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AXNX Price Action

Last 7 days

53.1%

Last 30 days

-2.6%

Last 90 days

-56.1%

Trailing 12 Months

-98.9%

AXNX RSI Chart

AXNX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AXNX Valuation

Market Cap

51.6M

Price/Earnings (Trailing)

-9.12

Price/Sales (Trailing)

0.12

EV/EBITDA

-19.79

Price/Free Cashflow

9.61

AXNX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AXNX Fundamentals

AXNX Revenue

AXNX Earnings

AXNX Profitability

Free Cashflow Yield

10.41%

AXNX Investor Care

Revenue & Growth

How Axonics Modulation Technologies Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2024387.1M408.8M431.9M-
2023295.9M319.8M342.6M366.4M
2022194.3M217.4M240.9M273.7M
2021119.6M150.3M161.9M180.3M
202039.0M52.8M86.7M111.5M
20191.8M3.3M4.4M13.8M
2018-302.3K504.7K707.0K
2017---100.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Axonics Modulation Technologies Inc

AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
 CEO
 WEBSITEaxonics.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES610

Axonics Modulation Technologies Inc Frequently Asked Questions

AXNX is the stock ticker symbol of Axonics Modulation Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Oct 26 2026, market cap of Axonics Modulation Technologies Inc is 51.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Oct 26 2026, AXNX's PE ratio (Price to Earnings) is -9.12 and Price to Sales (PS) ratio is 0.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXNX PE ratio will change depending on the future growth rate expectations of investors.